



Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

Alessio Bruni^{1*}, Vieri Scotti², Paolo Borghetti³, Stefano Vagge⁴, Salvatore Cozzi⁵, Elisa D'Angelo¹, Niccolò Giaj Levra⁶, Alessandra Fozza⁴, Maria Taraborrelli⁷, Gaia Piperno⁸, Valentina Vanoni⁹, Matteo Sepulcri¹⁰, Marco Trovò¹¹, Valerio Nardone¹², Elisabetta Lattanzi¹³, Said Bou Selman¹⁴, Federica Bertolini¹⁵, Davide Franceschini¹⁶, Francesco Agustoni¹⁷, Barbara Alicja Jereczek-Fossa^{8,18}, Stefano Maria Magrini³, Lorenzo Livi², Frank Lohr¹ and Andrea Riccardo Filippi¹⁹

OPEN ACCESS

Edited and reviewed by:

Aditya Juloori,
University of Chicago Medical Center,
United States

*Correspondence:

Alessio Bruni
bruni.alessio@aou.mo.it

Specialty section:

This article was submitted to
Radiation Oncology,
a section of the journal
Frontiers in Oncology

Received: 27 October 2021

Accepted: 04 November 2021

Published: 16 November 2021

Citation:

Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D'Angelo E, Giaj Levra N, Fozza A, Taraborrelli M, Piperno G, Vanoni V, Sepulcri M, Trovò M, Nardone V, Lattanzi E, Bou Selman S, Bertolini F, Franceschini D, Agustoni F, Jereczek-Fossa BA, Magrini SM, Livi L, Lohr F and Filippi AR (2021) Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. *Front. Oncol.* 11:802949. doi: 10.3389/fonc.2021.802949

¹ Radiotherapy Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy, ² Department of Oncology, Radiation Therapy Unit, Careggi University Hospital, Florence, Italy, ³ Radiation Oncology Department, Spedali Civili and University of Brescia, Brescia, Italy, ⁴ Department of Radiation Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Martino, Genova, Italy, ⁵ Radiation Therapy Department, Arcispedale di Santa Maria Nuova IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Reggio Emilia, Italy, ⁶ Advanced Radiation Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Sacro Cuore Don Calabria Hospital, Verona, Italy, ⁷ Radiation Oncology Department, SS. Annunziata Hospital, "G. D'Annunzio" University of Chieti, Chieti, Italy, ⁸ Division of Radiotherapy, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) European Institute of Oncology, Milan, Italy, ⁹ Radiation Oncology Department, S. Chiara Hospital, Trento, Italy, ¹⁰ Radiation Oncology Unit, Veneto Institute of Oncology Istituto Oncologico Veneto (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy, ¹¹ Radiation Oncology Department, Azienda Sanitaria Universitaria Integrata, Udine, Italy, ¹² Radiotherapy Unit, "Ospedale del Mare", Naples, Italy, ¹³ Radiotherapy Unit, University Hospital of Parma, Parma, Italy, ¹⁴ Department of Radiotherapy, Bolzano Hospital, Bolzano, Italy, ¹⁵ Medical Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy, ¹⁶ Department of Radiotherapy and Radiosurgery, Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Humanitas Research Hospital, Milan, Italy, ¹⁷ Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy, ¹⁸ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, ¹⁹ Department of Radiation Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo and University of Pavia, Pavia, Italy

Keywords: chemoradiotherapy, immunotherapy, stage III, unresectable, NSCLC

A Corrigendum on

A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

By Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D'Angelo E, Giaj Levra N, Fozza A, Taraborrelli M, Piperno G, Vanoni V, Sepulcri M, Trovò M, Nardone V, Lattanzi E, Bou Selman S, Bertolini F, Franceschini D, Agustoni F, Jereczek-Fossa BA, Magrini SM, Livi L, Lohr F and Filippi AR. (2021). *Front. Oncol.* 11:744956. doi: 10.3389/fonc.2021.744956

In the original article there was an error. **The survival numbers were incorrect.**

A correction has been made to **Abstract:**

“1-year PFS and OS were 83.5% (95%CI: 77.6-89.7) and 97.2% (95%CI: 94.6-99.9), respectively.”

“1-year PFS and OS were 65.5% (95%CI: 57.6-74.4) and 87.9% (95%CI: 82.26-93.9), respectively”

In the original article, there was an error. **The survival numbers were incorrect.**

A correction has been made to **Results, Survival:**

“PFS at 12, 18, and 24 months was 83.5% (95%CI: 77.6–89.7), 65.5 (95%CI: 57.6–74.4), and 53.1% (95%CI: 43.8–64.3), respectively. (Figure 1). OS at 12, 18, and 24 months was 97.2% (95%CI: 94.6– 99.9), 87.9% (95%CI: 82.26–93.9), and 79.3% (95%CI: 71.1–88.4), respectively (Figure 1).”

“PFS at 6, 12, and 18 months was 83.5% (95%CI: 77.6–89.7), 65.5% (95%CI: 57.6–74.4), and 53.1% (95%CI: 43.8–64.3), respectively. (Figure 1). OS at 6, 12, and 18 months was 97.2% (95%CI: 94.6– 99.9), 87.9% (95%CI: 82.26–93.9), and 79.3% (95%CI: 71.1–88.4), respectively (Figure 1)”

In the original article, there was an error. **The survival numbers were incorrect.**

A correction has been made to **Discussion:**

“12-month PFS was 83.5%, and OS 97.2%”

“12-month PFS was 65.5%, and OS 87.9%”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Bruni, Scotti, Borghetti, Vagge, Cozzi, D’Angelo, Giaj Levra, Fozza, Taraborrelli, Piperno, Vanoni, Sepulcri, Trovò, Nardone, Lattanzi, Bou Selman, Bertolini, Franceschini, Agustoni, Jerezek-Fossa, Magrini, Livi, Lohr and Filippi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.